The risk of heart failure exacerbations was lower in the GLP-1 RAs group compared to non-GLP-1 RAs users (75.3 % vs. 80.8 %; HR 0.83; 95 % CI: 0.81–0.86; p < 0.001) with NNT of 18.2. This evidence concerns the gene GLP1R and heart failure.